Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Comparative Neuroprotective Effects of Dexamethasone and Minocycline during Hepatic Encephalopathy.

Gamal M, Abdel Wahab Z, Eshra M, Rashed L, Sharawy N.

Neurol Res Int. 2014;2014:254683. doi: 10.1155/2014/254683. Epub 2014 Feb 17.

2.

The effect of memantine and levodopa/carbidopa on the responses of phrenic nerve-diaphragm preparations from aged rats.

El-Moursy SA, Shawky HM, Abdel Wahab Z, Rashed L.

Med Sci Monit. 2009 Nov;15(11):BR339-48.

PMID:
19865051
3.

Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.

Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK.

Ann Surg Oncol. 2006 Dec;13(12):1645-54.

PMID:
16957968
4.

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.

Ueno T, Ko SH, Grubbs E, Yoshimoto Y, Augustine C, Abdel-Wahab Z, Cheng TY, Abdel-Wahab OI, Pruitt SK, Friedman HS, Tyler DS.

Mol Cancer Ther. 2006 Mar;5(3):732-8.

5.

Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.

Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, Chu E, Pruitt SK, Friedman HS, Dewhirst MW, Tyler DS.

Clin Cancer Res. 2006 Jan 1;12(1):289-97.

6.

Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.

Abdel-Wahab Z, Cisco R, Dannull J, Ueno T, Abdel-Wahab O, Kalady MF, Onaitis MW, Tyler DS, Pruitt SK.

J Surg Res. 2005 Apr;124(2):264-73.

PMID:
15820257
7.

In-transit melanoma: the role of alkylating-agent resistance in regional therapy.

Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS.

J Am Coll Surg. 2004 Sep;199(3):419-27.

PMID:
15325612
8.

Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4.

Cisco RM, Abdel-Wahab Z, Dannull J, Nair S, Tyler DS, Gilboa E, Vieweg J, Daaka Y, Pruitt SK.

J Immunol. 2004 Jun 1;172(11):7162-8.

9.

Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.

Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK.

J Surg Res. 2004 Jan;116(1):24-31.

PMID:
14732346
10.

Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.

Abdel-Wahab Z, Kalady MF, Emani S, Onaitis MW, Abdel-Wahab OI, Cisco R, Wheless L, Cheng TY, Tyler DS, Pruitt SK.

Cell Immunol. 2003 Aug;224(2):86-97.

PMID:
14609574
11.

CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.

Onaitis MW, Kalady MF, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK.

Surgery. 2003 Aug;134(2):300-5.

PMID:
12947333
12.
13.
14.
15.

Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice.

DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF.

Cell Immunol. 1998 Apr 10;185(1):65-74.

PMID:
9636684
16.

Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.

DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H.

J Surg Oncol. 1998 Jun;68(2):79-91. Review.

PMID:
9624036
17.

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.

Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF.

Cancer. 1997 Aug 1;80(3):401-12. Erratum in: Cancer 1999 Oct 1;86(7):1380.

PMID:
9241074
18.

Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.

Abdel-Wahab Z, Dar M, Osanto S, Fong T, Vervaert CE, Hester D, Jolly D, Seigler HF.

Cancer Gene Ther. 1997 Jan-Feb;4(1):33-41.

PMID:
9012449
19.

Modulation of specific active immunization against murine melanoma using recombinant cytokines.

Stidham KR, Ricci WM, Vervaert C, Abdel-Wahab Z, Seigler HF, Darrow TL.

Surg Oncol. 1996 Oct-Dec;5(5-6):221-9.

PMID:
9129134
20.

Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2.

Darrow TL, Abdel-Wahab Z, Quinn-Allen MA, Seigler HF.

Cell Immunol. 1996 Aug 25;172(1):52-9.

PMID:
8806806
21.

Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.

Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, Darrow TL, Seigler HF.

Cell Immunol. 1996 Aug 1;171(2):246-54.

PMID:
8806794
22.

Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.

Kubo H, Abe J, Obata F, Nakajima H, Tsunoda M, Ogawa A, Nakayama S, Beck Y, Kohsaka T, Darrow TL, Abdel-Wahab Z, Saida T, Takiguchi M.

Cancer Res. 1996 May 15;56(10):2368-74.

23.

Immunological memory induced by genetically transduced tumor cells.

Dar MM, Abdel-Wahab Z, Vervaert CE, Darrow T, Barber J, Seigler HF.

Ann Surg Oncol. 1996 May;3(3):247-54.

PMID:
8726179
24.

Immunotherapy of Human Melanoma With Gene-Modified Tumor Cell Vaccines.

Darrow TL, Abdel-Wahab Z, Seigler HF.

Cancer Control. 1995 Oct;2(5):415-423.

PMID:
10862182
25.

Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model.

Abdel-Wahab Z, Li WP, Osanto S, Darrow TL, Hessling J, Vervaert CE, Burrascano M, Barber J, Seigler HF.

Cell Immunol. 1994 Nov;159(1):26-39.

PMID:
7954840
26.

Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.

Abdel-Wahab ZA, Osanto S, Darrow TL, Barber JR, Vervaert CE, Gangavalli R, McCallister TJ, Seigler HF.

Cancer Gene Ther. 1994 Sep;1(3):171-9.

PMID:
7621248
27.

A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma.

Seigler HF, Darrow TL, Abdel-Wahab Z, Gangavalli R, Barber J.

Hum Gene Ther. 1994 Jun;5(6):761-77. No abstract available.

PMID:
7948138
28.

Retrovirus-mediated gene transfer of the human gamma-IFN gene: a therapy for cancer.

Howard B, Burrascano M, McCallister T, Chong K, Gangavalli R, Severinsson L, Jolly DJ, Darrow T, Vervaert C, Abdel-Wahab Z, et al.

Ann N Y Acad Sci. 1994 May 31;716:167-87.

PMID:
8024193
29.

Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.

Abdel-Wahab Z, Li WP, Darrow T, Nudelman ED, Towell A, Seigler HF.

Melanoma Res. 1993 Dec;3(6):415-23.

PMID:
8161881
30.

Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.

Abdel-Wahab ZA, Darrow TL, Vervaert CE, Giannopoulou AA, Li W, Seigler HF.

Surg Oncol. 1992 Apr;1(2):115-25.

PMID:
1341242
31.

Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient.

Abdel-wahab ZA, Gillanders WE, Darrow TL, Seigler HF.

Hum Antibodies Hybridomas. 1992 Jan;3(1):32-9.

PMID:
1576321
32.

Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody.

Abdel-Wahab Z, Darrow T, Vervaert CE, Crowley NJ, Seigler HF.

Mol Biother. 1991 Sep;3(3):163-9.

PMID:
1768367

Supplemental Content

Loading ...
Support Center